Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Legend Biotech (LEGN) Interest Expenses (2019 - 2025)

Historic Interest Expenses for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to -$5.6 million.

  • Legend Biotech's Interest Expenses fell 239.83% to -$5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.8 million, marking a year-over-year increase of 6476.89%. This contributed to the annual value of -$21615.0 for FY2024, which is 82.13% up from last year.
  • Latest data reveals that Legend Biotech reported Interest Expenses of -$5.6 million as of Q3 2025, which was down 239.83% from -$5.2 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Interest Expenses registered a high of $5.1 million during Q1 2023, and its lowest value of -$5.7 million during Q3 2023.
  • Its 5-year average for Interest Expenses is -$2.1 million, with a median of -$1.6 million in 2022.
  • Its Interest Expenses has fluctuated over the past 5 years, first plummeted by 305961.54% in 2022, then skyrocketed by 58975.1% in 2023.
  • Over the past 5 years, Legend Biotech's Interest Expenses (Quarter) stood at -$602000.0 in 2021, then crashed by 707.48% to -$4.9 million in 2022, then surged by 99.88% to -$5820.0 in 2023, then increased by 11.48% to -$5152.0 in 2024, then crashed by 109294.41% to -$5.6 million in 2025.
  • Its Interest Expenses stands at -$5.6 million for Q3 2025, versus -$5.2 million for Q2 2025 and $5.1 million for Q1 2025.